- Home
- FULC vs AURA Comparison
FULC vs AURA Comparison
Compare FULC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- AURA
- Stock Information
- Founded
- FULC 2015
- AURA 2007
- Country
- FULC United States
- AURA United States
- Employees
- FULC N/A
- AURA N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- AURA Health Care
- Exchange
- FULC Nasdaq
- AURA Nasdaq
- Market Cap
- FULC 469.0M
- AURA 396.8M
- IPO Year
- FULC 2019
- AURA 2021
- Fundamental
- Price
- FULC $8.73
- AURA $6.13
- Analyst Decision
- FULC Buy
- AURA Strong Buy
- Analyst Count
- FULC 6
- AURA 7
- Target Price
- FULC $8.67
- AURA $22.29
- AVG Volume (30 Days)
- FULC 524.6K
- AURA 284.2K
- Earning Date
- FULC 11-12-2025
- AURA 11-11-2025
- Dividend Yield
- FULC N/A
- AURA N/A
- EPS Growth
- FULC N/A
- AURA N/A
- EPS
- FULC N/A
- AURA N/A
- Revenue
- FULC N/A
- AURA N/A
- Revenue This Year
- FULC N/A
- AURA N/A
- Revenue Next Year
- FULC N/A
- AURA N/A
- P/E Ratio
- FULC N/A
- AURA N/A
- Revenue Growth
- FULC 2752.05
- AURA N/A
- 52 Week Low
- FULC $2.32
- AURA $4.35
- 52 Week High
- FULC $9.88
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- FULC 54.66
- AURA 49.86
- Support Level
- FULC $9.10
- AURA $5.72
- Resistance Level
- FULC $9.88
- AURA $6.14
- Average True Range (ATR)
- FULC 0.57
- AURA 0.28
- MACD
- FULC -0.02
- AURA 0.02
- Stochastic Oscillator
- FULC 56.24
- AURA 65.15
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.